中国临床药理学杂志2011，Vol.27Issue(8)：607-611,5.
CYP2C19基因多态性对伏立康唑药代动力学影响的系统评价
Systematic review of influence on pharmacokinetics of voriconazole on CYP2C19 genetic polymorphisms
王瓅珏 1唐惠林 2段京莉1
作者信息
- 1. 北京大学,第三医院药剂科,北京,100191
- 2. 北京大学,医学部药学院药事管理与临床药学系,北京,100191
- 折叠
摘要
Abstract
Objective To evaluate the influence of CYP2C19 genetic polymorphisms on voriconazole pharmacokinetics. Methods Cochrane library, PubMed, Embase, CNKI databases were searched by computer for investigating the influence of CYP2C19 genetic polymorphisms on voriconazole pharmacokinetics. The researches were reported before February 2010. The Meta analysis was performed by RevMan 5. 0 software. Results Ten retrospective studies, with 9 literatures in English and 1 literature in Chinese. The results of Meta analysis showed: There was no statistically significant among three genotypes of Cmax; Differences among the AUC and T1/2 is very obvious, PM genotype group were greater than the HEM genotype, and the HEM genotype group were significantly higher than EM genotype group. EM genotype group was significantly greater than PM genotype group in CL/F, PM genotype group was significantly longer than EM group in Tmax, PM genotype group was significantly greater than the EM group in MRT. Conclusion Voriconazole exposure is not only influenced by CYP2C19 genetic polymorphism, but by other reasons, and large sample prospective studies are needed.关键词
伏立康唑/细胞色素P4502C19/基因多态性Key words
voriconazole/CYP2C19/genetic polymorphism分类
医药卫生引用本文复制引用
王瓅珏,唐惠林,段京莉..CYP2C19基因多态性对伏立康唑药代动力学影响的系统评价[J].中国临床药理学杂志,2011,27(8):607-611,5.
